Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTAIN: Aclidinium Bromide in Moderate to Severe COPD
NCT01001494Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2009
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of aclidinium in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Started Oct 2009; status: completed.
02
Drugs
aclidinium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01001494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01001494.